



**Fig. S1. Fraction of BrdU-positive mesenchymal cells at different forelimb bud stages.**

(A) Representative FACS analysis shows the BrdU incorporation into wild-type forelimb buds at E9.75 (26-29 somites,  $n=5$  independent samples), E10.75 (36-40 somites,  $n=4$ ) and E11.75 (48-52 somites,  $n=5$ ). Numbers indicate the percentage of BrdU-positive cells. (B) Percentage of BrdU-positive cells in wild-type forelimb buds (E9.75:  $n=5$ , E10.75:  $n=4$  and E11.75:  $n=5$  independent samples).




**Fig. S2. Spatial distribution of markers used to identify specific mesenchymal cell populations in forelimb buds.**

Immunohistochemistry shows the spatial distribution of the SOX9, PDGFR $\alpha$  and JAG1 proteins in mid-sagittal sections of mouse forelimb buds at E10.5 and E11.5. Note that the mesenchymal cells expressing JAG1 at E11.5 overlap with SOX9-positive cells in the anterior mesenchyme. This was confirmed by FACS analysis. Therefore, JAG1 is only marking the posterior-distal and SOX9-negative mesenchymal cells in early forelimb buds at E10.5 (see also Fig. 2). White dashed lines outline limb bud. Scale bars: 50  $\mu$ m.



**Figure S3. GO analysis of the genes expressed differentially in the forelimb bud mesenchymal cell populations at E10.5-E10.75.**


(A, B) GO analysis of the genes whose expression is higher (panel A) and lower than average (panel B) in the S9-SCA-1<sup>+</sup> mesenchymal cell population. (C-F) GO analysis of genes expressed at lower than average levels in S9-JAG1<sup>+</sup> LMPs (panel C), S9-Pα<sup>hi</sup> LMPs (panel D), S9<sup>+</sup>Pα<sup>hi</sup> OCPs (panel E) and S9<sup>+</sup>Pα<sup>hi</sup>Col2a1<sup>+</sup> chondroblasts (panel F). Asterisks indicate chondrogenesis- and limb-related GO terms.




**Fig. S4. SHH pathway analysis.**

(A) Limb mesenchymal cells were cultured for 12 hours in presence of different concentrations of cyclopamine (0-20 $\mu\text{M}$ ). Graph showing relative *Gli1* expression levels as determined by RT-qPCR. Individual data points plus mean  $\pm$  SD are shown (n=2 data points per concentration). (B) Apoptosis rate assessed by Annexin-V in lineage-negative limb bud culture cells treated with 20 $\mu\text{M}$  cyclopamine (Cyc) or solvent alone (Co). Individual data points plus mean  $\pm$  SD are shown (n=11). (C) Quantification of cell cycle stages occupied by limb mesenchymal cells after 12 hours of cyclopamine treatment. Individual data points plus mean  $\pm$  SD are shown (n=10). Statistical evaluation of all results was done using the Wilcoxon test: (\*\*) p-value  $\leq 0.01$ .



**A**




**B**






**C**



**D**




**E**



**Fig. S5. FGF pathway analysis.**

(A) S9-JAG1<sup>+</sup>LMPs express highest levels of the *Spry* and *Dusp6* transcriptional targets of FGF signaling in limb buds. (B) Forelimb bud mesenchymal cells (E10.5) were cultured for 12 hours in medium supplemented with FGF8b (300ng/mL) or solvent alone (Co). The fractions cells at the different stages of the cell cycle were quantitated by FACS. Individual data points plus mean  $\pm$  SD are shown (n=7). (C) The effects of the FGF8b treatment on *Spry4* and *Dusp6* expression levels in cultured mesenchymal cells was determined by RT-qPCR (levels in control cultures were set arbitrary to 1). (D) Lin<sup>-</sup> mesenchymal cells undergoing apoptosis in control and FGF8b-treated cultures. Individual data points plus mean  $\pm$  SD are shown (n=7). (E) FACS quantitation of the different stages of the cell cycle in limb bud mesenchymal cells (controls versus FGF8b treated). Individual data points plus mean  $\pm$  SD are shown (n=7). (F) Comparative analysis of the fractions (%) of S9-JAG1<sup>+</sup> and S9-P $\alpha$ <sup>hi</sup> LMPs and S9<sup>+</sup>P $\alpha$ <sup>hi</sup> OCPs in control and FGF8b treated cultures. Statistical evaluation of all results was done using the Wilcoxon test: (\*) p-value  $\leq$ 0.05.



**Fig. S6. BMP and *Grem1* pathway analysis.**

(A) Limb mesenchymal cells (E10.5) were cultured for 12 hours in medium supplemented with solvent (Co) or 5  $\mu$ M Dorsomorphin (Dm). This reduces the expression of the direct transcriptional target *Id1* as determined by RT-qPCR analysis. Individual data points plus mean  $\pm$  SD are shown (n=6). (B) FACS was used to determine the fraction of apoptotic cells isolated from wild-type (Wt) and *Grem1*-deficient forelimb buds (*Grem1* <sup>$\Delta\Delta$</sup> ) at E10.5. Individual data points plus mean  $\pm$  SD are shown (n=8 for *Grem1* <sup>$\Delta\Delta$</sup> ; n=17 for Wt). Statistical evaluation of all results was done using the Wilcoxon test: (\*) p-value  $\leq$ 0.05.

**Table S1.** Values myogenic-lineage-specific genes

[Click here to Download Table S1](#)

**Table S2.** Differentially expressed genes (DEGs) Sca-1 population

[Click here to Download Table S2](#)

**Table S3.** DEGs Jag1

[Click here to Download Table S3](#)

**Table S4.** DEGs PDGFRa

[Click here to Download Table S4](#)

**Table S5.** DEGs OCPs

[Click here to Download Table S5](#)



**Table S6.** DEGs chondroblasts

[Click here to Download Table S6](#)

**Table S7.** Data for the switch-peak heatmap

[Click here to Download Table S7](#)

**Table S8.** Data for “Smoothened (SMO) signaling pathway” (GO:0007224)

[Click here to Download Table S8](#)

**Table S9.** Data for “Cellular response to BMP stimulus” (GO:0071773)

[Click here to Download Table S9](#)

**Table S10.** Data for manually curated list of transcription factors with essential functions during limb development (subset of Table S7)

[Click here to Download Table S10](#)

**Table S11.** The oligos used for gene expression analysis

*Acan fwd:* 5'-AGTCAACCGTTGCAGACCAG-3'

*Acan rev:* 5'-GGTCATGAAAGTGGCGGTAA-3'

*BMP4 fwd:* 5'-AGCCGAGCCAACACTGTGA-3'

*BMP4 rev:* 5'-GTTCTCCAGATGTTCTTCGTGATG-3'

*Col2a1 fwd:* 5'-AGTGGAAGAGCGGAGACTACTG-3'

*Col2a1 rev:* 5'-TTGGGGTAGACGCCAAGTCTC-3'

*Id1 fwd:* 5'-GCGAGATCAGTGCCTTGG-3'

*Id1 rev:* 5'-CTCCTGAAGGGCTGGAGT-3'

*Gli1 fwd:* 5'-CAAGTGCACGTTTGAAG-3'

*Gli1 rev:* 5'-CAACCTTCTTGCTCACACATGTAAG-3'

*Dusp6 fwd:* 5'-AGTTTTTCCCTGAGGCCATT-3'

*Dusp6 rev:* 5'-GCATCGTTCATGGACAGGTT-3'

*Grem1 fwd:* 5'-CCCACGGAAGTGACAGAATGA-3'

*Grem1 rev:* 5'-AAGCAACGCTCCCACAGTGTA-3'

*Jag1 fwd:* 5'- GCGGTTGCAGAAGTCAGAGT-3'

*Jag1 rev:* 5'- AGGCTGTCACCAAGCAACAG -3'

*Msx2 fwd:* 5'-ATACAGGAGCCCGGCAGATACT-3'

*Msx2 rev:* 5'-TCCGGTTGGTCTTGTGTTTCC-3'

*Spry4 fwd:* 5'-TGTGACTCTGCA GCTCCTCAA-3'

*Spry4 rev:* 5'-ATGAGGCTGGAGGTCCTGAACT-3'

*Sox9 fwd:* 5'-CAAGTGTGTGTGCCGTGGATAG-3'

*Sox9 rev:* 5'-CCAGCCACAGCAGTGAGTAAGAA-3'

*Rpl19 fwd:* 5'-ACCCTGGCCCGACGG-3'

*Rpl19 rev:* 5'-TACCCTTTCCTCTCCCTATGCC-3'